Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • mholiv@lemmy.worldEnglish
    171·
    3 days ago

    You need to reach out to the scientists to let them know! You could save lives with your insight!